Sotatercept Helps the Sickest Patients With Pulmonary Arterial Hypertension

Watchdoq April 1, 2025
(MedPage Today) -- CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial.
Among 172 patients, the drug reduced the...

Read Full Article